The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Sugammadex Lorien sugammadex sodium Generic | LABORATORIOS LORIEN, S.L | 🇪🇺 EU | Order → | |
| Sumatriptan Galpharm sumatriptan Generic | Galpharm Healthcare Ltd. | Migraine Disorders | 🇪🇺 EU 2011-11-17 | Order → |
| Surfaxin sinapultide;dipalmitoylphosphatidylcholine;palmitoyl-oleoyl phosphatidylglycerol;palmitic acid Orphan | Pharm Research Associates (UK) Limited | Respiratory Distress Syndrome, Newborn | 🇪🇺 EU | Order → |
| Susvimo ranibizumab | Roche Registration GmbH | Wet Macular Degeneration | 🇪🇺 EU | Order → |
| Syfovre pegcetacoplan | Apellis Europe B.V. | Macular Degeneration; Geographic Atrophy | 🇪🇺 EU 2024-09-19 | Order → |
| Synordia fenofibrate;metformin | Fournier Laboratories Ireland Ltd. | Diabetes Mellitus, Type 2 | 🇪🇺 EU | Order → |
| Tacquell Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded | Netherlands Cancer Institute | Melanoma | 🇪🇺 EU 2026-06-25 | Order → |
| Tekinex omacetaxine mepesuccinate | ChemGenex Europe SAS | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 🇪🇺 EU | Order → |
| Teriparatide Ascend teriparatide Biosimilar | Ascend GmbH | Osteoporosis; Osteoporosis, Postmenopausal; Bone Resorption | 🇪🇺 EU | Order → |
| Teriparatide Cinnagen teriparatide Biosimilar | CinnaGen Co Unipessoal LDA | Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU | Order → |
| Theraloc nimotuzumab Orphan | Oncoscience AG | Glioma | 🇪🇺 EU | Order → |
| Thymanax agomelatine | Les Laboratoires Servier | Depressive Disorder, Major | 🇪🇺 EU 2006-07-27 | Order → |
| Tibsovo ivosidenib | Agios Netherlands B.V. | Leukemia, Myeloid, Acute | 🇪🇺 EU | Order → |
| Tidhesco ivosidenib Orphan | Les Laboratoires Servier | Leukemia, Myeloid, Acute | 🇪🇺 EU | Order → |
| Tigecycline Accord tigecycline Generic | Accord Healthcare Ltd | Soft Tissue Infections | 🇪🇺 EU | Order → |
| Tolvaptan Accord tolvaptan Generic | Accord Healthcare S.L.U. | Inappropriate ADH Syndrome | 🇪🇺 EU 2023-01-26 | Order → |
| Topotecan SUN topotecan Generic | Sun Pharmaceutical Industries Europe B.V. | 🇪🇺 EU | Order → | |
| Treprostinil SciPharm Sàrl treprostinil | SciPharm Sàrl | Hypertension, Pulmonary | 🇪🇺 EU | Order → |
| Turalio pexidartinib OrphanAdditional monitoring | Daiichi Sankyo Europe GmbH | Giant Cell Tumor of Tendon Sheath; Synovitis, Pigmented Villonodular | 🇪🇺 EU 2020-06-25 | Order → |
| Tuznue trastuzumab Biosimilar | Prestige Biopharma Belgium | Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.